Suboptimal use of cardioprotective drugs in newly treated elderly individuals with type 2 diabetes

Diabetes Care

Volumn 30, Issue 7, 2007, Pages 1880-1882

  Sirois, Caroline ^a,b,c   Moisan, Jocelyne ^a,b   Poirier, Paul ^a,d   Grégoire, Jean Pierre ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; INSULIN; ORAL ANTIDIABETIC AGENT;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ELDERLY CARE; FEMALE; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPHYLAXIS;

ADMINISTRATION, ORAL; AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PLATELET AGGREGATION INHIBITORS;

EID: 34447128050     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2257     Document Type: Article

References (21)

1. Bertoni AG, Krop JS, Anderson GF, Brancati FL: Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care 25:471-475, 2002
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153, 2000
3. Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016, 2003
4. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755-1762, 1998
5. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
6. Klinke JA, Johnson JA, Guirguis LM, Toth EL, Lee TK, Lewanczuk RZ, Majumdar SR: Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada. Clin Ther 26:439-446, 2004
7. Toth EL, Majumdar SR, Guiguis LM, Lewanczuk RZ, Lee TK, Johnson JA: Compliance with clinical practice guidelines for type 2 diabetes in rural patients: treatment gaps and opportunities for improvement. Pharmacotherapy 23:659-665, 2003
8. Saaddine JB, Cadwell B, Gregg EW, Engelgau MM, Vinicor F, Imperatore G, Narayan KM: Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 144:465-474, 2006
9. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
10. Emberson JR, Whincup PH, Lawlor DA, Montaner D, Ebrahim S: Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women. Heart 91:451-455, 2005
11. Shah BR, Huz JE, Laupacis A, Zinman B, Booth GL: Use of vascular risk-modifying medications for diabetic patients differs between physician specialties. Diabet Med 23:1117-1123, 2006
12. Brown CL, Johnson JA, Majumdar SR, Tsuyiki RT, McAlister AF: Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 171:1189-1192, 2004
13. Safford M, Eaton L, Hawley G, Brimacombe M, Rajan M, Li H, Pogach L: Disparities in use of lipid-lowering medications among people with type 2 diabetes mellitus. Arch Intern Med 163:922-938, 2003
14. Ferrara A, Williamson DF, Karter AJ, Thompson TJ, Kim C: Sex differences in quality of health care related to ischemic heart disease prevention in patients with diabetes: the translating research into action for Diabetes (TRIAD) study, 2000-2001. Diabetes Care 27:2974-2976, 2004
15. Kopp A, Mamdani M, Shah BR: Drug use in older people with diabetes. In Diabetes in Ontario: An ICES Practice Atlas Booth GL, Hux JE, Laupacis A, Slaughter PM, Eds. Toronto, Institute for Clinical Evaluative Sciences, 2003, p. 3.51-53.75
16. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E: Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 28:514-520, 2005
17. Nau DP, Mallya U: Sex disparity in the management of dyslipidemia among patients with type 2 diabetes mellitus in a managed care organization. Am J Manag Care 11:69-73, 2005
18. Petri A, de Lusignan S, Williams J, Chan T, Majeed A: Management of cardiovascular risk factors in people with diabetes in primary care: cross-sectional study. Public Health 120:654-663, 2006
19. Canadian Diabetes Association: Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 27 (Suppl. 2):S1-S152, 2003
20. American Diabetes Association: Standards of medical care in diabetes - 2007 (Position Statement). Diabetes Care 30 (Suppl. 1):S4-S41, 2007
21. Rosen AB: Indications for and utilization of ACE inhibitors in older individuals with diabetes: findings from the National Health and Nutrition Examination Survey 1999-2002. J Gen Intern Med 4:315-319, 2006